ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor ...
UroToday16h
ASCO GU 2025: Outcomes for 177Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with mCRPC
GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Miguel Muniz discussing outcomes for 177 Lu-PSMA-617 with and without concurrent use of androgen receptor pathway ...
Renal & Urology News17h
Real-World Data Confirm Better Survival With Lutetium-177 vs Cabazitaxel in mCRPC
Real-world data support trial data on the use of lutetium-177 PSMA-617 in patients with PSMA-positive, metastatic castration-resistant prostate cancer.
UroToday17h
ASCO GU 2025: Impact of Baseline PSMA PET in Patients with mCRPC Starting First-Line Androgen Receptor Signaling Inhibitor Therapy
(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Ivan de Kouchkovsky discussing the impact of baseline PSMA PET in patients with metastatic ...